Back

Double-stranded RNA responses, neoantigen presentation and suppression of hepatocellular carcinoma through NMD inhibition via endonuclease SMG6

Arpa, E. S.; Ricci, V.; Shapiro, I. E.; Jokic, M.; Gonzalez Menendez, I.; Quintanilla-Fend, L.; Benechet, A. P.; Rehwinkel, J.; Luther, S. A.; Bassani-Sternberg, M.; Gatfield, D.

2025-01-15 cancer biology
10.1101/2025.01.13.632668 bioRxiv
Show abstract

The nonsense-mediated mRNA decay (NMD) pathway degrades transcripts bearing premature termination codons (PTCs), typically arising from mutations and RNA processing errors, to prevent the accumulation of aberrant proteins. Its role in cancer is complex, with both tumor-promoting and tumor-suppressive functions described. Here, we selectively inhibit NMD in the liver by conditionally inactivating its endonuclease SMG6 in a genetic mouse model of hepatocellular carcinoma. SMG6 inactivation completely abrogates tumor formation and elicits both innate and adaptive immune responses. Mechanistically, SMG6 deficiency activates the type I interferon response via the double-stranded RNA (dsRNA) sensor MDA5, uncovering a physiological role for NMD in regulating cytoplasmic dsRNA levels. In parallel, stabilization and translation of NMD-target transcripts generate non-canonical immunopeptides presented by MHC-I, promoting potent CD8+ T-cell responses. These findings establish SMG6-dependent NMD as a core orchestrator of immune tolerance in cancer and reveal that its selective inhibition in cancer cells unleashes immunogenic transcript expression with therapeutic potential.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.